Summary

Catheters and Active Implantable CDMO Market Research Report Information By Service Category (Catheters, Active Implantable Devices, Endoscopy Devices, and Others), By End-Users (Medical Device OEM Companies, Academic and Research Institutes, and Government Agencies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032


Overview of the Market
In 2023, the market for active implantable CDMOs and catheters was estimated to be worth USD 6.92 billion. With a compound annual growth rate (CAGR) of 10.82% from 2024 to 2032, the sector is expected to increase from USD 7.49 billion in 2024 to USD 18.8 billion by 2032.
The market is growing because of more manufacturing outsourcing and growing strategic initiatives related to catheters and active implantable CDMO.
The global market for catheters and active implanted CDMOs is expanding significantly because of growing initiatives that are fostering innovation and enhancing market accessibility. Strategic mergers and acquisitions enable companies to offer comprehensive solutions and accelerate product development by combining resources and expertise. At the same time, increased investments in healthcare infrastructure, especially in emerging nations, and a growing need for minimally invasive procedures are driving up the usage of advanced catheters and implantable devices.

Perspectives on Market Segments
The Catheters and Active Implantable CDMO Market has been divided into three segments based on the service segment: endoscopy devices, active implantable devices, and catheters.
The Catheters and Active Implantable CDMO Market is divided into government organizations, academic and research institutions, and medical device OEM firms based on the end user.

Regional Perspectives
In 2023, North America held the biggest market share, which it is expected to maintain throughout the forecast period. Nonetheless, over the course of the forecast period, Asia-Pacific is anticipated to develop at the greatest CAGR.
The market for active implantable CDMOs in North America is expanding rapidly due to a favorable regulatory environment, growing healthcare demands, and technology breakthroughs. Furthermore, the market is driven by advanced healthcare infrastructure and significant research & development spending that makes it possible to create innovative implantable devices. Additionally, there are growth prospects due to the rise of customized treatment, the need for minimally invasive solutions, and prospects for expansion into new countries.
Europe, which is further divided into Germany, France, the United Kingdom, Italy, Spain, and the Rest of Europe, comes after the Americas. The market for active implantable CDMOs in Europe has a lot of room to grow thanks to increased healthcare demands and technology developments. The need for specialized manufacturing knowledge is being driven by technological improvements in implantable devices, including insulin pumps, neurostimulators, and next-generation cardiac pacemakers. The need for advanced, superior implanted solutions is further increased by the aging population and the rising incidence of chronic diseases.
Over the course of the forecast period, Asia-Pacific is anticipated to expand at the fastest rate and see substantial expansion due to several important variables. The need for advanced implantable devices is being driven by the quick development of medical technology and rising investments in healthcare infrastructure in nations like China, India, and Japan. The need for creative solutions is further fueled by the aging population, diabetes, and the increasing prevalence of chronic diseases.

Key Players

Integer Holdings Corporation (US), Cirtec (US), Biomerics (US), Switchback Medical (US), Velentium LLC (US), Heraeus Group (Germany), Zeus Company LLC (US), Veranex (US), Freudenberg Medical (US), and Medeologix (Taiwan) are the leading companies in the catheter and active implantable CDMO market.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.2.1 Data Mining Process
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 Secondary Research data flow:
3.5 PRIMARY RESEARCH:
3.5.1 Primary Research DATA FLOW:
3.5.2 Primary Research: Number of Interviews conducted
3.5.3 Primary Research: Regional Coverage
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 Revenue Analysis Approach
3.7 DATA FORECASTING
3.7.1 Data forecasting Technique
3.8 DATA MODELING
3.8.1 microeconomic factor analysis:
3.8.2 Data modeling:
3.9 TEAMS AND ANALYST CONTRIBUTION
4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 Increasing strategic initiatives associated with Catheters and Active Implantable CDMO
4.2.2 Increased Outsourcing of Manufacturing
4.3 RESTRAINTS
4.3.1 Stringent regulatory Policies
4.4 OPPORTUNITY
4.4.1 Growing geriatric population across the globe
4.4.2 FACILITY EXPANSION by Contract Development Manuacturing Organization
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL
5.1.1 Threat of New Entrants
5.1.2 Bargaining Power of Suppliers
5.1.3 Threat of Substitutes
5.1.4 Bargaining Power of Buyers
5.1.5 Intensity of Rivalry
5.2 IMPACT OF COVID-19 ON THE GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET
5.3 TRENDS IN CDMO FOR CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET
5.3.1 Shifting Focus of Medical Device CDMOs to Improve Capabilities
6 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY SERVICE CATEGORY
6.1 OVERVIEW
6.2 CATHETERS
6.2.1 Cardiac Catheters
6.2.2 Urology Catheters
6.2.3 Neurovascular Catheters
6.2.4 Others
6.3 ACTIVE IMPLANTABLE DEVICES
6.3.1 Neuromodulation Devices
6.3.1.1 Spinal Cord Stimulators
6.3.1.2 Deep Brain Stimulators
6.3.1.3 Others
6.3.2 Structural Heart Devices
6.3.2.1 Valve Implants
6.3.2.2 Stents & Shunts
6.3.2.3 Others
6.3.3 Heart Failure Devices
6.3.3.1 Percutaneous Left Ventricular Assist Device (LVAD)
6.3.3.2 Percutaneous Right Ventricular Support Devices (RVAD)
6.3.3.3 Others
6.3.4 Urology Implantable Devices
6.3.5 Others
6.4 ENDOSCOPY DEVICES
6.5 OTHERS
7 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY END USER
7.1 OVERVIEW
7.2 MEDICAL DEVICE OEM COMPANIES
7.3 ACADEMIC AND RESEARCH INSTITUTES
7.4 GOVERNMENT AGENCIES
8 GLOBAL CATHETERS AND ACTIVE IMPLANTABLE CDMO MARKET, BY REGION
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 US
8.2.2 Canada
8.3 EUROPE
8.3.1 Germany
8.3.2 France
8.3.3 UK
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 ASIA-PACIFIC
8.4.1 China
8.4.2 India
8.4.3 Japan
8.4.4 South Korea
8.4.5 Australia
8.4.6 Rest of Asia-Pacific
8.5 REST OF THE WORLD
8.5.1 Middle East & Africa
8.5.2 South America
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION
9.2 MARKET SHARE ANALYSIS, 2023
9.3 COMPETITOR DASHBOARD
9.4 PUBLIC PLAYERS STOCK SUMMARY
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
9.6.1 Facility expansion
9.6.2 Acquisition
9.6.3 Partnership
10 COMPANY PROFILES
10.1 INTEGER HOLDINGS CORPORATION
10.1.1 COMPANY OVERVIEW
10.1.2 FINANCIAL OVERVIEW
10.1.3 productS OFFERED
10.1.4 KEY DEVELOPMENTS
10.1.5 SWOT ANALYSIS
10.1.6 KEY STRATEGIES
10.2 CIRTEC
10.2.1 COMPANY OVERVIEW
10.2.2 FINANCIAL OVERVIEW
10.2.3 PRODUCT OFFERED
10.2.4 KEY DEVELOPMENTS
10.2.5 SWOT ANALYSIS
10.2.6 KEY STRATEGIES
10.3 BIOMERICS
10.3.1 COMPANY OVERVIEW
10.3.2 FINANCIAL OVERVIEW
10.3.3 PRODUCTS OFFERED
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIES
10.4 SWITCHBACK MEDICAL
10.4.1 COMPANY OVERVIEW
10.4.2 FINANCIAL OVERVIEW
10.4.3 PRODUCTS OFFERED
10.4.4 KEY DEVELOPMENTS
10.4.5 SWOT ANALYSIS
10.4.6 KEY STRATEGIES
10.5 VELENTIUM LLC
10.5.1 COMPANY OVERVIEW
10.5.2 FINANCIAL OVERVIEW
10.5.3 PRODUCTS OFFERED
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIES
10.6 HERAEUS GROUP
10.6.1 COMPANY OVERVIEW
10.6.2 FINANCIAL OVERVIEW
10.6.3 PRODUCTS OFFERED
10.6.4 KEY DEVELOPMENTS
10.6.5 SWOT ANALYSIS
10.6.6 KEY STRATEGIES
10.7 ZEUS COMPANY LLC
10.7.1 COMPANY OVERVIEW
10.7.2 FINANCIAL OVERVIEW
10.7.3 PRODUCTS OFFERED
10.7.4 KEY DEVELOPMENTS
10.7.5 SWOT ANALYSIS
10.7.6 KEY STRATEGIES
10.8 VERANEX
10.8.1 COMPANY OVERVIEw
10.8.2 FINANCIAL OVERVIEW
10.8.3 Product OFFERed
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIES
10.9 FREUDENBERG MEDICAL
10.9.1 COMPANY OVERVIEW
10.9.2 FINANCIAL OVERVIEW
10.9.3 PRODUCTS OFFERED
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIES
10.10 MEDEOLOGIX
10.10.1 COMPANY OVERVIEW
10.10.2 FINANCIAL OVERVIEW
10.10.3 PRODUCTS OFFERED
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIES
10.11 DATA CITATIONS